EQS-News: FamiCord AG starts 2025 financial year with accelerated growth and increases profitability at almost all earnings levels

FamiCord AG starts 2025 financial year with accelerated growth and increases profitability at almost all earnings levels

• Group revenue increases significantly by 19.0 percent to EUR 22.1 million
• EBITDA rises sharply by 76.3 percent to EUR 2.7 million following investments in sales & marketing particularly in Poland and Germany as well as cost-cutting measures
• Higher proportion of annual payers in new customer business causes operating cash flow to fall to EUR 1.3 million in the short term
• Guidance for 2025 confirmed in terms of sales and earnings

Leipzig, 28 May 2025 – FamiCord AG, the leading cell bank in Europe and the third largest worldwide, grew significantly at the start of the year while at the same time substantially improving its profitability. An increasing stabilization of demand coupled with optimized contract structures and increasingly efficient cost structures led to an increasingly broad improvement in key financial figures.

In the first quarter of 2025, Group revenue increased by 19.0 percent year-on-year to EUR 22.1 million (Q1 2024: EUR 18.6 million). The net amount of invoiced services in the end customer business (B2C) rose by 5.2 percent to EUR 19.0 million (Q1 2024: EUR 18.0 million), while the share of annually recurring payments increased by 5.7 percent to EUR 6.0 million (Q1 2024: EUR 5.7 million). “Our growth is increasingly gaining momentum and, after several successful quarters in a row, we can rightly speak of a stable growth trend again. Although there is no doubt that the current economic situation in Europe points to a bumpy year in 2025 we are well prepared for this and accordingly confident that we will be able to cope with this difficult situation,” explains Jakub Baran, CEO of FamiCord AG. “We will of course stay on the ball in order to continue delivering quarter after quarter as we did in 2024.”

From a regional perspective, the recovery in the core markets is continuing. In the Eastern European market, demand is increasingly strengthening and is already showing noticeable growth momentum again. In the Central European market, the company was able to achieve slight organic growth again for the first time, although the development is not yet showing a steady trend. The only exceptions were individual markets in Southern Europe, where demand continued to decline. In the current year, the company will therefore introduce further measures to increase efficiency in these markets in order to at least significantly improve the earnings situation.

At EUR 2.7 million, earnings before interest, taxes, depreciation and amortization (EBITDA) once again grew disproportionately by 76.3 percent (Q1 2024: EUR 1.5 million). The significant increase in profitability is evidence of the successful implementation of measures to increase efficiency over the course of 2024. At the same time, optimized contract structures for both contract renewals and new customer contracts had a positive impact on the quality of earnings. However, the financial result, which was impacted by unfavorable exchange rate effects and hyperinflationary effects in Turkey, had a significant negative effect on the net result.

The key figures for business development developed as follows:

At EUR 1.3 million, operating cash flow was significantly below the previous year's level (Q1 2024: EUR 4.0 million). The main reason for the significant decline was the high demand for annual payer contracts in new customer business. Although these strengthen the long-term basis of business development, they have a negative impact on cash flow development in the short term. In addition, the Company benefited from a one-off tax refund in the same period of the previous year. Cash and cash equivalents nevertheless improved by 1.5 percent to EUR 17.1 million (31.12.2024: EUR 16.8 million), underlining the overall solid financial position as the basis for continued sales growth. “In 2025, we will focus in particular on the targeted improvement of individual key financial figures. From a financial perspective, we are in a solid position overall. But of course there is room for improvement in the coming quarters,” emphasizes Thomas Pfaadt, CFO of FamiCord AG.

FamiCord's Management Board is convinced that the Company is in a good position to cope well with the economic situation throughout Europe, which is increasingly characterized by recessionary trends. In view of the increasingly improved quality of earnings, the Management Board is therefore confirming its guidance for the full year 2025, which assumes revenue of between EUR 85 million and EUR 95 million with EBITDA of between EUR 8.7 million and EUR 10.3 million. The forecast is based on a constant exchange rate of the euro against the Polish zloty and other currencies (HUF, RON, TRY, GBP, AED).

The Management Board of FamiCord AG will be available to institutional investors, analysts and members of the press today at 9:00 a.m. CEST in a video conference to provide additional information on business development. To register for this, please send an e-mail to the Investor Relations department (ir@famicord.com).

Further information on FamiCord and its affiliated subsidiaries can be found at www.famicord.com.

Contact: 
FamiCord AG
Ingo Middelmenne
Investor Relations
Phone: +49 (0341) 48792 40
Email: ingo.middelmenne@famicord.com

Company profile

FamiCord (formerly Vita 34) was founded in Leipzig in 1997 and today is by far the leading cell bank in Europe and the third largest worldwide. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has since offered the collection logistics, processing and storage of stem cells from umbilical cord blood, umbilical cord tissue and other postnatal tissues as a full-service provider for cryopreservation. The donor's own cells are a valuable starting material for medical cell therapy and are kept alive in the vapor of liquid nitrogen. Customers from about 50 countries have already provided for the health of their families with about one million units of stored biological material at FamiCord. Furthermore, the Company is active in the areas of Cell & Gene therapies and CDMO.